期刊文献+

血清微小RNA-451a表达对弥漫大B细胞淋巴瘤患者化疗效果的预测价值 被引量:2

Predictive value of serum microRNA-451a expression in the clinical treatment of diffuse large B cell lymphoma
下载PDF
导出
摘要 目的探究血清微小RNA-451a(miR-451a)表达对弥漫大B细胞淋巴瘤(DLBCL)患者化疗效果的预测价值。方法选取广东药科大学附属第一医院2017年2月至2019年2月收治的78例DLBCL患者,根据化疗效果分为化疗有效组(53例)和化疗无效组(25例)。同时选取53例相同年龄段体检健康者为对照组。分别收集DLBCL患者化疗前后的血清样本以及对照组的血清样本,通过实时荧光定量聚合酶链反应检测血清中miR-451a的表达水平。采用受试者工作特征曲线评估miR-451a对DLBCL患者化疗效果的预测价值。结果DLBCL患者化疗前血清miR-451a表达量明显低于对照组[(0.69±0.27)比(1.86±0.65)](P<0.05)。化疗有效组DLBCL患者化疗后血清miR-451a表达量较化疗前明显上升[(1.46±0.63)比(0.81±0.36)](P<0.05)。DLBCL患者化疗前血清miR-451a表达与Ann Arbor分期和国际预后指数评分有关(均P<0.05)。血清miR-451a预测DLBCL患者化疗是否有效的曲线下面积为0.816,敏感度为83.0%、特异度为84.0%,最佳截断值为0.72。结论DLBCL患者血清中miR-451a表达下调,且与Ann Arbor分期和国际预后指数评分有关,在评估患者化疗效果方面有一定的应用价值。 Objective To investigate predictive value of serum microRNA(miR)-451 a expression in the clinical treatment of diffuse large B cell lymphoma(DLBCL).Methods Totally 78 DLBCL patients admitted to the First Affiliated Hospital of Guangdong Pharmaceutical University from February 2017 to February 2019 were selected.The patients were divided into effective group(53 cases)and ineffective group(25 cases),and53 healthy persons of the same period were selected as control group.Serum samples of DLBCL patients before and after chemotherapy and serum samples of control group were collected,and the expression level of miR-451 a in serum was measured by real-time fluorescent quantitative polymerase chain reaction.The diagnostic value of miR-451 a in the efficacy of chemotherapy was evaluated by using the receiver operating characteristic curve.Results The expression level of miR-451 a in serum of DLBCL patients before chemotherapy was lower than that of control group[(0.69±0.27)vs(1.86±0.65)](P<0.05).The expression level of miR-451 a in the effective group was higher than that before chemotherapy[(1.46±0.63)vs(0.81±0.36)](P<0.05).The expression of miR-451 a in serum of DLBCL patients was related to Ann Arbor staging and international prognostic index(IPI)score(all P<0.05).The area under curve of serum miR-451 a in the diagnosis of chemotherapy efficacy was0.816,the sensitivity and specificity were 83.0%and 84.0%,respectively,and the optimal cut-off value was0.72.Conclusion The expression of miR-451 a in serum of DLBCL is down-regulated and related to Ann Arbor staging and IPI score,which has certain application value in the detection of chemotherapy effect.
作者 温珍珍 潘学谊 Wen Zhenzhen;Pan Xueyi(Department of Hematology,the First Affiliated Hospital of Guangdong Pharmaceutical University,Cuangzhou 510080,China)
出处 《中国医药》 2020年第12期1917-1920,共4页 China Medicine
基金 广东省自然科学基金(2017A030313664) 广州市越秀区科技计划(2017-W S-008)。
关键词 弥漫大B细胞淋巴瘤 微小RNA-451a 受试者工作特征曲线 化疗 Diffuse large B cell lymphoma MicroRNA-451a Receiver operating characteristic curve Chemotherapy
  • 相关文献

参考文献5

二级参考文献54

  • 1张彦宁,周小鸽,张淑红,王鹏,张长淮,黄受方.非霍奇金B细胞淋巴瘤369例病理形态观察 2001年世界卫生组织淋巴组织肿瘤新分类应用体会[J].中华病理学杂志,2005,34(4):193-197. 被引量:36
  • 2吴宏菊,张清媛,陈德发,关小军,张伯龙,马军.美罗华联合CHOP方案与CHOP方案治疗初治弥漫性大B细胞淋巴瘤的临床对比研究[J].癌症,2005,24(12):1498-1502. 被引量:33
  • 3Korl AD, le Gessie S, Snijder S, et al. Primary extranodal non- Hodgkin' s lymphoma (NHL): the impact of alternative defini- tions tested in the Comprehensive Cancer Centre West popula- tion-based NHL registry. Ann Oncol, 2003, 14:131-139.
  • 4Li XQ, Li GD, Gao ZF, et al. The relative frequencies of lympho- ma subtypes in China: a nationwide study of 10002 cases by the Chinese Lymphoma Study Group. Ann Oncol, 2011, 22 Suppl 4: ivl41.
  • 5Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a stan- dard regimen (CHOP) with three intensive chemotherapy regi- mens for advanced non-Hodgkin' s lymphoma. N Engl J Med, 1993, 328:1002-1006.
  • 6Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med, 2005, 352:1197-1205.
  • 7Coiffier B, Thieblemont C, Van Den Neste E,et ah Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemother- apy in DLBCL patients: a study by the Grouped' Etudes des Lymphomes de 1' Adulte. Blood, 2010, 116:2040-2045.
  • 8Seki R, Ohshima K, Nagafuji K, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol, 2010, 9 I: 258-266.
  • 9Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 2005, 23:5027-5033.
  • 10Habermama TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in old- er patients with diffuse large B-cell lymphoma. J Clin Oncol, 2006, 24:3121-3127.

共引文献275

同被引文献19

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部